Metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) are differentiated by the presence of cardiometabolic risk factors (CMRFs) and insulin resistance (IR). This study aimed to evaluate the prevalence and clinical characteristics of MHO in Korean children and adolescents and to investigate the anthropometric, laboratory, and lifestyle predictors of MHO. This study included data from 530 obese subjects, aged 10–19 years, obtained from the Fourth Korea National Health and Nutrition Examination Survey. Subjects were classified into MHO and MUO groups according to the presence of CMRF (MHO_CMRF/MUO_CMRF) and degree of IR (MHO_IR/MUO_IR). Demographic, anthropometric, cardiometabolic, and lifestyle factors were compared between the groups. Logistic regression analysis and receiver operating characteristic curve analysis were performed to identify factors that predicted MHO. The prevalence of MHO_CMRF and MHO_IR in obese Korean youth was 36.8% (n = 197) and 68.8% (n = 356), respectively. CMRF profiles were significantly less favorable in MUO children. Longer and more vigorous physical activity and less protein intake were associated with MHO_CMRF phenotype. The best predictors of MHO_CMRF and MHO_IR were waist circumference (odds ratio [OR], 0.82; 95% confidence interval [CI], 0.77–0.88; P < 0.001) and body mass index (BMI) standard deviation score (OR, 0.24; 95% CI, 0.15–0.39; P < 0.001), respectively. The prevalence of MHO differed depending on how it was defined. To adequately manage obesity in youth, the approach to individuals with MHO and MUO should be personalized due to variation in clinical characteristics. Longitudinal studies are needed to evaluate long-term consequences of MHO.

Keywords: Metabolically Healthy Obesity; Prevalence; Children; Korea

INTRODUCTION

The increasing prevalence of obesity in children and adolescents is becoming a global concern (1,2). Childhood obesity can lead to obesity in adulthood and increase the risk of hypertension, type 2 diabetes mellitus, hyperlipidemia, cardiovascular disease, psychological morbidity, and premature mortality (3,4). However, some obese subjects do not have obesity-related comorbidities (5).

Metabolically healthy obesity (MHO) is described as an obesity phenotype without cardiometabolic risk factors (CMRFs) such as insulin resistance (IR), hypertension, and dyslipidemia. By contrast, metabolically unhealthy obesity (MUO) refers to obesity with CMRFs. The definition of MHO in children and adolescents varies considerably, resulting in a broad range of MHO prevalence reported in obese subjects (between 22% and 68%) (6-9). In previous studies, the MHO phenotype has been associated with favorable metabolic, physical activity (PA), and dietary profiles compared with the MUO phenotype (6,7,10-16). Despite these positive findings of the MHO phenotype, several studies have reported no differences in PA levels between individuals with MHO and MUO (17-19).

To date, only a few studies have investigated the prevalence and clinical characteristics of MHO in children and adolescents. Furthermore, previous studies were conducted in limited populations. Therefore, this study aimed to evaluate the prevalence and clinical characteristics of MHO in obese Korean children and adolescents, to compare the demographic, anthropometric, laboratory, and lifestyle factors of the MHO and MUO phenotypes, and to investigate the predictors of MHO by using data obtained from the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV).
**MATERIALS AND METHODS**

**Study population**
This study was conducted using data obtained from the KNHANES IV (2007–2009). The KNHANES is a cross-sectional survey of the non-institutionalized Korean population. It is a nationally representative survey that has been performed periodically since 1998 by the Division of Chronic Disease Surveillance, Korea Centers for Disease Control and Prevention. A multi-stage clustered probability design was applied to this survey (20).

A total of 24,871 individuals are included in the KNHANES IV. Among them, 3,364 children and adolescents aged 10–19 years were identified as potential candidates for the present study. Among the 3,364 subjects, a total of 530 obese youths (321 boys [60.6%] and 209 girls [39.4%]) were included in the present study after excluding non-obese subjects (n = 2,010), subjects who had fasted for less than 8 hours (n = 321) prior to the blood test, and subjects missing test results for any of the components used to evaluate cardiometabolic risk (n = 530).

Anthropometric measurements were obtained for all participants by trained personnel. Height was determined to the nearest 0.1 cm with a portable stadiometer (Seca 225; Seca, Hamburg, Germany). Weight was measured to the nearest 0.1 kg on a medical balance scale (GL-6000-20; CAS, Seoul, Korea). Body mass index (BMI) was calculated as weight (kg) divided by height squared (m²). Height, weight, and BMI standard deviation score (SDS) was calculated using the 2007 Korean Growth Chart (21). Waist circumference (WC) was measured at the midpoint between the lowest margin of the rib and the uppermost lateral border of the iliac crest during expiration using a flexible tape (Seca 220; Seca). Waist-height ratio (WHR) was calculated as WC divided by height (%). Blood pressure (BP) was measured on the right arm after the subject had rested for 5 minutes in a seated position using a mercury sphygmomanometer (Baumanometer® Desk model 0320; W.A. Baum, Copiague, NY, USA). Systolic and diastolic BP were measured in triplicate, and the second and third measurements were averaged and used in the analyses.

Blood was taken from each participant by trained medical personnel after overnight fasting. The samples were transported to a central laboratory after preparation and analyzed within 24 hours. Plasma glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, triglyceride (TG), and alanine transaminase (ALT) were measured using an ADIVA 1650 analyzer (Siemens, Washington, D.C., USA) in 2007 and a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan) in 2008 and 2009. Insulin was measured by an immunoradiometric assay (INS-IRMA; Biosource, Nivelles, Belgium) using a 1470 WIZARD gamma-counter (PerkinElmer, Turku, Finland). IR was evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR), which was calculated as (22):

\[
\text{HOMA-IR} = \frac{\text{fasting insulin (mIU/mL)} \times \text{fasting glucose (mmol/L)}}{22.5}
\]

All subjects and their parents or legal guardians were interviewed for surveys of PA and nutrition. For the PA survey, data on the duration and frequency of moderate PA, vigorous PA, and walking were collected. Structured questionnaires on PA were self-administered in a mobile examination center. Parents or legal guardians of children aged 10–11 years completed the questionnaires for their children. Questionnaires included questions about participation in vigorous and moderate PA, as well as how often the subject had walked for at least 10 minutes in the past 7 days. The total PA was calculated as the sum of vigorous PA, moderate PA, and walking expressed as minutes per day. Vigorous PA was defined as PA that caused large increases in breathing or heart rate. Moderate PA was defined as PA that caused a slight to moderate increase in breathing or heart rate. For the nutritional survey, the 24-hour dietary recall method was used to collect data on daily food intake. Average daily nutrient intake including carbohydrates, protein, and lipids was recorded by trained personnel.

**Definition of CMRFs and IR**
Obesity was defined by BMI ≥ 95th percentile for sex and age, or ≥ 25 kg/m² (21). CMRFs were defined using the components of metabolic syndrome defined by the International Diabetes Federation (23): systolic or diastolic BP ≥ 130/85 mmHg; fasting plasma glucose ≥ 100 mg/dL; TG ≥ 150 mg/dL; HDL cholesterol < 40 mg/dL in boys aged 10–19 years and girls aged 10–15 years and < 50 mg/dL in girls aged between 16–19 years. IR was defined as HOMA-IR ≥ 95th percentile for age and sex using Korean reference data (24).

MHO and MUO phenotypes were classified according to two different criteria, which were the presence/absence of CMRF(s) and the degree of IR. Obese subjects without any CMRF was defined as having MHO by risk factors (MHO\_CMRF), and those with one or more CMRF was defined as having MUO by risk factors (MUO\_CMRF) (7,13,25). Obese subjects without IR was defined as having MHO by IR (MHO\_IR), and those with IR as having MUO by IR (MUO\_IR).

**Statistical analysis**
Statistical analyses were performed with Stata 14.2 software (StataCorp LP, College Station, TX, USA). Data were analyzed using Stata survey tools appropriate for the KNHANES sampling design. Results are expressed as the weighted mean ± standard error (SE) or number of cases (weighted percent). We compared the average values of demographic, anthropometric, cardiometabolic, and lifestyle factors between MHO and MUO subjects. Multiple logistic regression analysis was performed to determine the odds ratio (OR) with 95% confidence interval (CI) for association between MHO phenotype and anthropometry-, diet-,
and PA-related variables with adjustment for age and sex. Backward stepwise elimination with a significance level for removal from the model of 0.1 was applied for selection of the best subset of variables. Receiver operating characteristic (ROC) curve analysis was performed to identify the area under the curve (AUC) and its 95% CI for predicting MUO using anthropometric variables. P values of < 0.05 were considered statistically significant.

Ethics statement
All participants in the KNHANES IV provided informed consent. The protocol of the KNHANES IV was approved by the Institutional Review Board of the Korea Centers for Disease Control and Prevention (2007-02CON-04-P, 2008-04EXP-01-C, and 2009-01-CON-03-2C). Our study was approved by the Institutional Review Board of Inje University Ilsan Paik Hospital (2015-08-004). All procedures were performed in accordance with the Declaration of Helsinki.

RESULTS

Clinical characteristics of study participants
Among 530 obese subjects, 193 (36.8%) were classified as having MHO_MCRF and 356 (68.8%) as having MHO_O (Table 1). Subjects were older in the MHO_MCRF group than in the MUO group (15.2 ± 0.2 vs. 14.5 ± 0.3, P = 0.019). No differences in age or sex were observed between the MHO_MCRF and MUO groups. Values of all anthropometric parameters were significantly higher in the MUO group (all P < 0.001). The levels of CMRFs (BP, total cholesterol, TG, fasting glucose, ALT, insulin, and HOMA-IR) were significantly lower in the MHO_MCRF group. HDL cholesterol-

Table 1. Demographic, anthropometric, CMRF, PA, and dietary characteristics of children and adolescents with MHO and MUO defined according to different definitions of MHO

| Variables                        | CMRFs                                      | P value | CMRFs                                      | P value |
|----------------------------------|--------------------------------------------|---------|--------------------------------------------|---------|
|                                  | MHO_MCRF (n = 197, 36.8%)                 |         | MHO_O (n = 356, 68.8%)                    |         |
|                                  | MHO_MCRF (n = 333, 63.2%)                 |         | MHO_O (n = 174, 31.2%)                    |         |
| Demography and anthropometry    |                                            |         |                                            |         |
| Age, yr                          | 14.8 ± 0.2                                 | 0.160   | 15.2 ± 0.2                                 | 0.019   |
| Sex, boys (%)                    | 112 (60.0)                                 | 0.225   | 216 (64.9)                                 | 0.523   |
| Height SDS                       | 0.35 ± 0.08                                | 0.002   | 0.44 ± 0.06                                | < 0.001 |
| Weight SDS                       | 1.11 ± 0.04                                | < 0.001 | 1.27 ± 0.04                                | < 0.001 |
| BMI SDS                          | 1.14 ± 0.03                                | < 0.001 | 1.26 ± 0.03                                | < 0.001 |
| WC, cm                           | 77.3 ± 0.5                                 | < 0.001 | 80.8 ± 0.5                                 | < 0.001 |
| WHR, %                           | 47.3 ± 0.2                                 | < 0.001 | 48.9 ± 0.2                                 | < 0.001 |
|                                   |                                            |         |                                            |         |
| CMRFs                            |                                            |         |                                            |         |
| Systolic BP, mmHg                | 105.9 ± 0.8                                | < 0.001 | 108.5 ± 0.7                                | 0.025   |
| Diastolic BP, mmHg               | 66.2 ± 0.6                                 | 0.002   | 67.5 ± 0.6                                 | 0.110   |
| Total cholesterol, mg/dL         | 159.7 ± 2.3                                | 0.013   | 163.0 ± 2.0                                | 0.293   |
| HDL cholesterol, mg/dL           | 50.2 ± 0.7                                 | < 0.001 | 46.6 ± 0.5                                 | 0.030   |
| TG, mg/dL                        | 78.5 ± 2.4                                 | < 0.001 | 95.9 ± 3.6                                 | < 0.001 |
| Insulin, mIU/L                   | 14.5 ± 0.4                                 | < 0.001 | 12.8 ± 0.2                                 | < 0.001 |
| Glucose, mg/dL                   | 88.6 ± 0.4                                 | < 0.001 | 88.5 ± 0.3                                 | < 0.001 |
| HOMA-IR                          | 3.2 ± 0.1                                  | < 0.001 | 2.8 ± 0.0                                  | < 0.001 |
| ALT, IU/L                        | 18.1 ± 1.1                                 | < 0.001 | 19.6 ± 0.9                                 | < 0.001 |
| PA                               |                                            |         |                                            |         |
| Moderate PA, min/day             | 14.8 ± 2.5                                 | 0.620   | 15.2 ± 1.9                                 | 0.078   |
| Vigorous PA, min/day             | 26.5 ± 4.3                                 | 0.077   | 22.0 ± 2.4                                 | 0.687   |
| Walk, min/day                    | 46.2 ± 5.1                                 | 0.858   | 51.5 ± 4.9                                 | 0.015   |
| Total PA, min/day                | 87.5 ± 8.2                                 | 0.390   | 88.7 ± 6.6                                 | 0.025   |
| Diet                             |                                            |         |                                            |         |
| Energy intake, kcal/day          | 1,945.9 ± 66.4                             | 0.413   | 2,031.0 ± 62.3                             | 0.225   |
| Carbohydrate intake, g/day       | 308.2 ± 9.5                                | 0.644   | 316.0 ± 9.2                                | 0.404   |
| Carbohydrate intake, %           | 64.2 ± 0.7                                 | 0.441   | 63.7 ± 0.7                                 | 0.917   |
| Protein intake, g/day            | 66.1 ± 2.3                                 | 0.029   | 72.1 ± 2.3                                 | 0.351   |
| Protein intake, %                | 13.8 ± 0.3                                 | 0.054   | 14.3 ± 0.2                                 | 0.833   |
| Fat intake, g/day                | 48.9 ± 2.7                                 | 0.431   | 52.2 ± 2.5                                 | 0.176   |
| Fat intake, %                    | 22.0 ± 0.6                                 | 0.868   | 21.9 ± 0.5                                 | 0.936   |
| Water intake, g/day              | 768.1 ± 41.8                               | 0.142   | 847.4 ± 39.8                               | 0.113   |
| Fiber intake, g/day              | 5.6 ± 0.3                                  | 0.430   | 5.7 ± 0.3                                  | 0.572   |

Data are expressed as weighted mean ± standard error or number of cases (weighted percent). PA = physical activity, MHO = metabolically healthy obesity, MUO = metabolically unhealthy obesity, CMRF = cardiometabolic risk factor, IR = insulin resistance, SDS = standard deviation score, BMI = body mass index, WC = waist circumference, WHR = waist-height ratio, BP = blood pressure, HDL = high-density lipoprotein, TG = triglyceride, HOMA-IR = homeostatic model assessment of insulin resistance, ALT = alanine transaminase.
ol was significantly higher in the MHO\textsubscript{CMRF} group (P < 0.001). Diastolic BP and total cholesterol did not significantly differ between the MHO\textsubscript{IR} and MUO\textsubscript{IR} groups. In the MUO\textsubscript{IR} group, 37.8%, 19.6%, 4.4%, and 1.4% of subjects had one, two, three, and four CMRFs, respectively (Fig. 1). The proportion of subjects with two or more CMRFs was lower in the MHO\textsubscript{IR} group than in the MUO\textsubscript{IR} group (Fig. 1). In subjects with the MUO\textsubscript{CMRF} phenotype, 45.2% had low HDL cholesterol, 28.0% had high TG, 16.5% had high BP, and 13.6% had elevated fasting glucose (Fig. 2). In the MUO\textsubscript{IR} group, the proportion of subjects with high TG and high fasting glucose was higher than that in the MHO\textsubscript{IR} group (Fig. 2).

Table 2. Associations between individual anthropometry-, diet-, and PA-related variables and MHO phenotype* according to different definitions of MHO

| Variables               | CMRFs OR | 95% CI     | P value | HOMA-IR OR | 95% CI     | P value |
|-------------------------|----------|------------|---------|------------|------------|---------|
| **Anthropometry and laboratory** |          |            |         |            |            |         |
| BMI SDS                 | 0.11     | 0.06–0.20  |< 0.001 | 0.27       | 0.18–0.41  |< 0.001 |
| WC, cm                  | 0.82     | 0.78–0.86  |< 0.001 | 0.92       | 0.90–0.95  |< 0.001 |
| WHR, %                  | 0.74     | 0.69–0.79  |< 0.001 | 0.89       | 0.85–0.93  |< 0.001 |
| Insulin, mIU/L          | 0.92     | 0.89–0.94  |< 0.001 | 0.49       | 0.43–0.56  |< 0.001 |
| Glucose, mg/dL          | 0.94     | 0.91–0.97  |< 0.001 | 0.89       | 0.86–0.92  |< 0.001 |
| HOMA-IR                 | 0.67     | 0.59–0.77  |< 0.001 | 0.02       | 0.01–0.04  |< 0.001 |
| ALT, IU/L               | 0.97     | 0.95–0.99  | 0.009   | 0.97       | 0.96–0.99  | 0.001   |
| **PA**                  |          |            |         |            |            |         |
| Moderate PA, min/day    | 1.00     | 1.00–1.01  | 0.575   | 1.01       | 1.00–1.01  | 0.142   |
| Vigorous PA, min/day    | 1.00     | 1.00–1.01  | 0.047   | 1.00       | 1.00–1.01  | 0.790   |
| Walk, min/day           | 1.00     | 1.00–1.00  | 0.929   | 1.00       | 1.00–1.01  | 0.031   |
| Total PA, min/day       | 1.00     | 1.00–1.00  | 0.291   | 1.00       | 1.00–1.01  | 0.082   |
| **Diet**                |          |            |         |            |            |         |
| Energy intake, kcal/day | 1.00     | 1.00–1.00  | 0.807   | 1.00       | 1.00–1.00  | 0.399   |
| Carbohydrate intake, kcal/day | 1.00     | 1.00–1.00  | 0.982   | 1.00       | 1.00–1.00  | 0.506   |
| Carbohydrate intake, %  | 1.00     | 0.98–1.03  | 0.654   | 1.00       | 0.98–1.03  | 0.786   |
| Protein intake, kcal/day| 0.99     | 0.99–1.00  | 0.098   | 1.00       | 0.99–1.01  | 0.585   |
| Protein intake, %       | 0.94     | 0.88–1.01  | 0.091   | 1.00       | 0.93–1.08  | 0.971   |
| Fat intake, kcal/day    | 1.00     | 0.99–1.01  | 0.797   | 1.00       | 1.00–1.01  | 0.414   |
| Fat intake, %           | 1.01     | 0.98–1.03  | 0.667   | 0.99       | 0.97–1.02  | 0.658   |
| Water intake, g/day     | 1.00     | 1.00–1.00  | 0.347   | 1.00       | 1.00–1.00  | 0.232   |
| Fiber intake, g/day     | 0.99     | 0.94–1.04  | 0.731   | 0.97       | 0.92–1.03  | 0.271   |

All ORs were adjusted for sex and age. CMRF = cardiometabolic risk factor, PA = physical activity, MHO = metabolically healthy obesity, HOMA-IR = homeostatic model assessment of insulin resistance, OR = odds ratio, CI = confidence interval, BMI = body mass index, SDS = standard deviation score, WC = waist circumference, WHR = waist-height ratio, ALT = alanine transaminase. *Reference variable: MUO, outcome variable: MHO.
the MHO\textsubscript{CMRF} and MUO\textsubscript{CMRF} groups (Table 1). However, total PA and walking time were significantly greater in the MHO\textsubscript{M} group. Among dietary factors including food intake habits (protein, carbohydrate, fat, fiber, and calorie intake), only daily protein intake (g/day) was significantly lower in the MHO\textsubscript{CMRF} group \((P = 0.029)\). No variables significantly differed between the MHO\textsubscript{M} and MUO\textsubscript{M} groups.

**Logistic regression analysis of clinical variables for the prediction of MHO**

In the age and sex-adjusted logistic regression analysis, WC, WHR, glucose, insulin level, HOMA-IR, and ALT were significantly associated with the MHO\textsubscript{CMRF} and MHO\textsubscript{M} phenotypes (Table 2). Among the factors related to PA, vigorous PA was associated with MHO\textsubscript{CMRF} (OR, 1.00; 95% CI, 1.00–1.01; \(P = 0.047\)) and walking with MHO\textsubscript{M} (OR, 1.00; 95% CI, 1.00–1.01; \(P = 0.031\)).

No dietary factors, including food intake habits (protein, carbohydrate, fat, fiber, and calorie intake), demonstrated a significant association with MHO\textsubscript{CMRF} or MHO\textsubscript{M}.

In the multiple logistic regression analysis, MHO\textsubscript{CMRF} was independently associated with BMI SDS, WC, vigorous PA, protein intake, and sex, whereas MHO\textsubscript{M} was associated with BMI SDS (OR, 0.24; 95% CI, 0.15–0.39; \(P < 0.001\)) (Table 3).

**Table 3. Multiple logistic regression analysis for the association of anthropometric and lifestyle-related variables with MHO phenotype defined by either set of criteria**

| Outcomes | Variables | OR     | 95% CI         | \(P\) value |
|----------|-----------|--------|----------------|-------------|
| MHO\textsubscript{CMRF} | BMI SDS | 0.34   | 0.15–0.76      | 0.009       |
|          | WC, cm   | 0.82   | 0.77–0.88      | < 0.001     |
|          | Vigorous PA, min/day | 1.02 | 1.01–1.03      | < 0.001     |
|          | Protein intake, g/day | 0.99 | 0.98–0.99      | 0.044       |
|          | Age, yr  | 0.94   | 0.83–1.07      | 0.366       |
|          | Sex      | 0.19   | 0.26–1.08      | 0.082       |
| MHO\textsubscript{M} | BMI SDS | 0.24   | 0.15–0.39      | < 0.001     |
|          | Total PA, min/day | 1.00 | 1.00–1.01      | 0.147       |
|          | Energy intake, kcal/day | 1.00 | 1.00–1.00      | 0.210       |
|          | Carbohydrate intake, % | 1.02 | 0.99–1.05      | 0.213       |
|          | Protein intake, % | 1.07 | 0.97–1.17      | 0.192       |
|          | Age, yr  | 1.10   | 1.00–1.22      | 0.058       |
|          | Sex      | 1.21   | 0.67–2.18      | 0.535       |

MHO = metabolically healthy obesity, OR = odds ratio, CI = confidence interval, BMI = body mass index, SDS = standard deviation score, WC = waist circumference, PA = physical activity, CMRF = cardiometabolic risk factor, IR = insulin resistance.

**Table 4. Associations of MHO phenotype with various factors using multiple logistic regression analysis**

| Variables | MHO\textsubscript{CMRF} | MHO\textsubscript{M} | \(P\) value |
|-----------|--------------------------|----------------------|-------------|
|           | AUC | 95% CI | AUC | 95% CI |       |
| BMI SDS   | 0.699 | 0.698–0.700 | 0.676 | 0.675–0.677 | < 0.001 |
| WHR, %    | 0.744 | 0.743–0.745 | 0.635 | 0.634–0.636 | < 0.001 |
| WC, cm    | 0.761 | 0.760–0.761 | 0.593 | 0.592–0.594 | < 0.001 |

MHO = metabolically healthy obesity, CMRF = cardiometabolic risk factor, MUO = metabolically unhealthy obesity, IR = insulin resistance.

**Fig. 3. ROC curve for BMI SDS, WHR, and WC to detect MHO by definition. (A) MHO\textsubscript{CMRF} with an AUC (95% CI) of 0.699 (0.698–0.700) for BMI SDS, 0.744 (0.743–0.745) for WHR, and 0.761 (0.760–0.761) for WC \((P < 0.001)\). (B) MHO\textsubscript{M} with an AUC (95% CI) of 0.676 (0.675–0.677) for BMI SDS, 0.635 (0.634–0.636) for WHR, and 0.593 (0.592–0.594) for WC \((P < 0.001)\). ROC = receiver operating characteristic, BMI = body mass index, SDS = standard deviation score, WHR = waist-height ratio, WC = waist circumference.**

**ROC curve analysis for the detection of MUO**

In the ROC curve analysis of the anthropometric factors associated with MHO (BMI SDS, WC, and WHR), the factor with the largest AUC was WC for MUO\textsubscript{CMRF} (AUC, 0.761; 95% CI, 0.760–0.761) and BMI SDS for MUO\textsubscript{M} (AUC, 0.676; 95% CI, 0.675–0.677) (Table 4, Fig. 3).

**DISCUSSION**

The objective of the present study was to investigate the prevalence of MHO in obese Korean children and adolescents and to compare the anthropometric, laboratory, and lifestyle factors between MHO and MUO. In this study, the prevalence of MHO in obese Korean children and adolescents was 36.8% \((n = 197)\) for CMRF criteria and 68.8% \((n = 356)\) for IR criteria. Longer time spent in vigorous PA and less protein intake was associated...
with the MHO\textsubscript{CMRF} phenotype. The best predictors of MUO\textsubscript{CMRF} and MUO\textsubscript{IR} were WC and BMI SDS, respectively.

Previous studies that defined MHO as obesity with no CMRFs reported a prevalence of MHO between 21.5% and 49.0% in pediatric populations (7,8,25,26). A study involving a Canadian pediatric population aged 8–17 years reported a different prevalence of MHO based on two different definitions of the phenotype (i.e., obesity with no CMRFs and obesity with a HOMA-IR of $\geq 3.16$). The prevalence of MHO according to these two definitions was 31.5% and 21.5%, respectively (7). The prevalence of MHO among obese adolescents in the United States was 68%, based on nationally representative data, which defined MHO as obesity with 0 or 1 abnormal CMRF (9). Because there is currently no established definition of MHO for adults and children, MHO prevalence differs widely between studies and populations (12). In the present study, the prevalence of MHO among obese youth differed depending on how it was defined. Moreover, the present results differ from the study carried out by Prince and colleagues (7), although the same definitions of MHO were applied, in that the difference of MHO prevalence defined by HOMA-IR was higher in our study. One possible reason for this discrepancy may be the different cutoff levels of HOMA-IR for IR used by the studies. In the present study, the cutoff was the 95th percentile of HOMA-IR for age and sex (3.52–5.01 for boys and 3.80–5.65 for girls). However, a HOMA-IR of 3.16 was applied in the previous study, which corresponds to approximately the 75–90th percentile of the Korean reference data (24). When applying the cutoff value of 3.16 for MHO to the subjects in the present study, the prevalence of MHO among obese Korean youth was 46.3%, which is closer to that reported by Prince and colleagues (data not shown) (7).

In the current study, CMRFs including systolic BP, TG, glucose, ALT, insulin, HOMA-IR, and HDL cholesterol were significantly more favorable in MHO subjects, which is consistent with previous studies. The most common laboratory abnormalities were low HDL cholesterol (45.2%) in the MUO\textsubscript{CMRF} group and high TG (32.9%) in the MUO\textsubscript{IR} group. In particular, significantly lower HOMA-IR levels were observed in the MHO\textsubscript{CMRF} group than in the MUO\textsubscript{CMRF} group, indicating higher rates of IR in the MUO group. Previous studies also reported IR in pediatric MUO populations. Vukovic et al. (27) reported that obese children in a lower quartile of HOMA-IR demonstrated a more favorable metabolic profile than those in a higher quartile of HOMA-IR. Preserved insulin sensitivity was observed in the MHO group. Moreover, the same research group suggested a HOMA-IR cutoff value of $\geq 2.85$ for diagnosing MUO, with 82% sensitivity and 60% specificity (6).

PA was not significantly different in the MHO and MUO groups (Table 1). However, after multiple logistic regression analysis (Table 3), vigorous PA was associated with MHO\textsubscript{CMRF} (OR, 1.02; $P < 0.001$). Total PA was not associated with MHO\textsubscript{IR} (OR, 1.00; $P = 0.147$). Consistent with the present study, Prince and colleagues (7) reported a difference in lifestyle factors (PA and screen time) in children and adolescents aged 8–17 years. They revealed that vigorous PA was an independent predictor for MHO defined by CMRFs and moderate-to-vigorous PA was an independent predictor for MHO defined by HOMA-IR. By contrast, another study found that PA was not associated with MHO and MUO phenotype in the pediatric population in the United States (9).

In adult populations, there have been conflicting results regarding the association between MHO/MUO phenotype and level of PA (9,14,17–19).

The discordance between result regarding PA might be the results of different methods employed across studies. Adult studies used various self-reporting questionnaires, the validity of which may not have been confirmed. Pediatric studies used self-reported questionnaires or parental responses (17). In one prospective study, PA was actually observed and recorded by a trained researcher over several days, as opposed to relying on self-reporting questionnaires (7), which may infer a higher level of validity for the results of that study.

In the present study, lower protein intake (g/day) was associated with the MHO\textsubscript{CMRF} phenotype, while dietary factors were not related to the MUO\textsubscript{IR} phenotype. Interestingly, dietary fat intake was not a predictor of MHO status in the present study population. Dietary fat consumption was previously reported to be a predictor of MHO defined using HOMA-IR, indicating that dietary fat might cause IR (7). A high-fat diet was also associated with IR in African Americans (28).

The difference in associations between MHO phenotype and dietary factors might be caused by the methods used to collect daily food consumption. For the nutritional survey in the present study, the 24-hour dietary recall method was used, which might lead to recall bias. Prince et al. (7) used prospective collection of food records for the evaluation of nutritional intake. Moreover, daily macronutrient intake differs between Korea and western countries. According to dietary reference intakes for Korean children, daily energy intake was 55%–65% carbohydrate, 15%–30% fat, and 7%–20% protein (29). However, in the United States, the proportion of carbohydrate, fat, and protein consumption per day was 45%–60%, 25%–35%, and 10%–35%, respectively (30). Further studies on the association between dietary factors and MHO phenotype are needed.

A previous study reported that WC can explain obesity-associated risks better than BMI (31). However, another study found that the BMI SDS was superior to WC for predicting cardiovascular risk factors (26). In the present study, the best anthropometric predictor for MUO\textsubscript{CMRF} was WC, and that for MUO\textsubscript{IR} was BMI SDS. However, in the present study, body composition could not be considered due to a lack of data. Applying these results to clinical settings, measurement of BMI SDS and WC could contribute to the detection of MUO.
There have been only a few longitudinal studies of the MHO/MUO phenotype in children and adolescents. A 1-year follow-up study of obese children revealed that pubertal stage is related to MHO and MUO status, and classification as MHO or MUO is unclear at least during the pubertal stage (26). A pilot study among obese adolescents showed that an earlier onset and a longer duration of obesity was associated with unhealthy metabolic characteristics in boys and not in girls (32).

There has been much skepticism around the existence of MHO. Based on an adult population study, MHO individuals showed increased mortality rates and cardiovascular risks compared to normal-weight individuals with normal metabolic profiles (33). However, it is well known that obesity during childhood and adolescence is linked to obesity in adulthood, and metabolically unhealthy adults clearly demonstrate higher morbidity and mortality rates. Therefore, children and adolescents with the MUO phenotype may have higher risk of cardiovascular problems and mortality compared to those with the MHO phenotype when they reach adulthood. Further longitudinal studies comparing morbidity and mortality rates between MUO and MHO groups are needed.

There were several limitations in the present study. First, due to the cross-sectional design of this study, it is difficult to identify causal relationships. Second, birth weight, puberty, family history, and body composition were not considered in the analysis due to a lack of data. However, to the best of our knowledge, this study is the first to investigate the prevalence and clinical features of MHO phenotype using different definitions in Korean children and adolescents with nationally representative data.

In conclusion, the prevalence of MHO in obese Korean children and adolescents was 36.8% as defined by CMRFs and 68.8% as defined by HOMA-IR. There were no differences between the MHO and MUO groups according to sex. The cardiometabolic profile was significantly less favorable in MUO children. The best anthropometric predictor of MUO was WC for MUO, and BMI SDS for MUO. To adequately manage obesity in children and adolescents, the approach to individuals with MHO and MUO subjects should be personalized due to their different clinical characteristics. Longitudinal studies of Korean MHO/MUO youth are needed to evaluate long-term consequences of MHO.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conceptualization: Kim JH. Data curation: Kim JH. Formal analysis: Lee J, Kim JH. Investigation: Yoon DY, Lee YA, Kim JH. Writing - original draft: Yoon DY, Kim JH. Writing - review & editing: Lee YA, Lee J, Shin CH, Yang SW.

ORCID

Da Young Yoon https://orcid.org/0000-0002-9604-554X
Young Ah Lee https://orcid.org/0000-0001-9179-1247
Jieun Lee https://orcid.org/0000-0002-9776-4204
Jae Hyun Kim https://orcid.org/0000-0002-2023-7443
Choong Ho Shin https://orcid.org/0000-0002-9813-1134
Sei Won Yang https://orcid.org/0000-0002-5304-5750

REFERENCES

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullaney EC, Biryukov S, Abbafati C, Abera SE et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-81.
2. Oh K, Jang MJ, Lee NY, Moon JS, Lee CG, Yoo MH, Kim YT. Prevalence and trends in obesity among Korean children and adolescents in 1997 and 2005. Korean J Pediatr 2008; 51: 950-5.
3. Reilly JJ. Descriptive epidemiology and health consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab 2005; 19: 327-41.
4. Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. Lancet 2002; 360: 473-82.
5. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism 2001; 50: 1499-504.
6. Vukovic R, Milenkovic T, Mitrovic K, Todorovic S, Plavsic L, Vukovic A, Zdravkovic D. Preserved insulin sensitivity predicts metabolically healthy obese phenotype in children and adolescents. Eur J Pediatr 2015; 174: 1649-55.
7. Prince RL, Kuk JL, Ambler KA, Dhaliwal J, Ball GD. Predictors of metabolically healthy obesity in children. Diabetes Care 2014; 37: 1462-8.
8. Wieghuber D, Zelzer S, Stelzer I, Paulmichl K, Kammerhofer D, Schnell W, Molnar D, Mangge H. High risk vs. “metabolically healthy” phenotype in juvenile obesity - neck subcutaneous adipose tissue and serum uric acid are clinically relevant. Exp Clin Endocrinol Diabetes 2013; 121: 384-90.
9. Camhi SM, Waring ME, Sisson SB, Hayman LL, Must A. Physical activity and screen time in metabolically healthy obese phenotypes in adolescents and adults. J Obes 2013; 2013: 984613.
10. Plourde G, Karelis AD. Current issues in the identification and treatment of metabolically healthy but obese individuals. Nutr Metab Cardiovasc Dis 2014; 24: 455-9.
11. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes 2011; 35: 971-81.
12. Blüher S, Schwarz P. Metabolically healthy obesity from childhood to adulthood - does weight status alone matter? Metabolism 2014; 63: 1084-92.
13. Mangge H, Zelzer S, Puerstner P, Schnell WJ, Reeves G, Postolache TT, Wieghuber D. Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity (Silver Spring) 2013; 21: E71-7.
14. Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P. Metabol-
Metabolically healthy obesity: different prevalences using different criteria. *Eur J Clin Nutr* 2010; 64: 1043-51.

15. Yoo HK, Choi EY, Park EW, Cheong YS, Bae RA. Comparison of metabolic characteristics of metabolically healthy but obese (MHO) middle-aged men according to different criteria. *Korean J Fam Med* 2013; 34: 19-26.

16. Phillips CM, Dillon C, Harrington JM, McCarthy VI, Kearney PM, Fitzgerald AP, Perry II. Defining metabolically healthy obesity: role of dietary and lifestyle factors. *PLoS One* 2013; 8: e76188.

17. Lee K. Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors. *Asia Pac J Clin Nutr* 2010; 64: 1043-51.

18. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? *J Clin Endocrinol Metab* 2001; 86: 1020-5.

19. Jennings CL, Lambert EV, Collins M, Joffe Y, Levitt NS, Goedecke JH. Determinants of insulin-resistant phenotypes in normal-weight and obese Black African women. *Obesity (Silver Spring)* 2008; 16: 1602-9.

20. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, Chun C, Kang YH, Oh K. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). *Int J Epidemiol* 2014; 43: 69-77.

21. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, Oh K, Jang MJ, Hwang SS, Yoo MH, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. *Korean J Pediatr* 2008; 51: 1-25.

22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412-9.

23. Zamrazilova H, Weiss R, Hainer V, Aldhoon-Hainerová I. Cardiometabolic health in obese adolescents is related to length of obesity exposure: a pilot study. *J Clin Endocrinol Metab* 2016; 101: 3088-95.

24. Kramer CK, Zimman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. *Ann Intern Med* 2013; 159: 758-69.